Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 7/20 | 0.41 |
| ▸ | PYGM | P11217 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799807 | 1.00 | MTNR1A (0.49) | MTNR1AMTNR1BMMEACEMAPT | |
| SCHEMBL14193208 | 0.86 | PYGL (0.43) | PYGLPYGM | |
| SCHEMBL4800980 | 0.86 | PYGL (0.43) | PYGLPYGM | |
| SCHEMBL4800991 | 0.86 | PYGL (0.43) | PYGLPYGM | |
| SCHEMBL13625990 | 0.80 | MTNR1A (0.49) | MTNR1AMTNR1BMMEACEMAPT | |
| SCHEMBL14193205 | 0.80 | SLC6A2 (0.50) | PYGLPYGM | |
| SCHEMBL9288876 | 0.77 | MMP1 (0.54) | MMEACE | |
| SCHEMBL13626167 | 0.74 | ACE (0.49) | MTNR1AMTNR1BMMEACE | |
| SCHEMBL7416568 | 0.74 | SCN9A (0.43) | ACE | |
| SCHEMBL7417159 | 0.73 | MMP1 (0.44) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40278-E1 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7074927-B2 | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | ROMERO ARTHUR G (US) | 2005-05-19 | — | — | US | disclosed |
| US-RE38452-E1 | SUITABLE FOR TREATING ANXIOLYTIC DISORDER, SCHIZOPHRENIA, PARKINSON'S DISEASE, ANXIETY | PHARMACIA & UPJOHN COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | ROMERO ARTHUR G (US) | 2001-07-26 | — | — | US | disclosed |
| EP-0724584-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5652245-A | Heterocyclic amines having central nervous system activity | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009916-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | CNR1, CNR2, OPRD1 | MTNR1A 64/4885MTNR1B 91/4885MME 2165/4885 |
| US-20050107378-A1 | Heterocyclic amines having central nervous system activity | CNR1, CNR2, NPY2R | MTNR1A 77/4885MTNR1B 109/4885MME 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.